Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know

Table 2 Studies evaluating the impact of the staging using magnetic resonance imaging in prostate cancer patients treated with radiotherapy

Ref.	Year	Type of MRI	No. of patients	Field strength	Coil	Tumor stage shift (%)	Risk group changes (%)	Change in RT (CTV, doses, HT) (%)	Technique validation
Jackson et al[75]	2005	Morphological	199	1.5T	PAB	55	NR	32.62	No
Couñago et al[76]	2014	Multiparametric	103	3T	PAB	94.1	33.9	33.9	Yes
Chang et al[77]	2014	Morphological	115	1.5T	PAB	68.6	7	201	No
Panje et al[8]	2015	multiparametric	122	1.5T and 3T	PAB	55.7	28.7	30	No
Horsley et al[78]	2015	Morphological	509	1.5T	PAB	20	9	18	No
Yamaguchi et al[79]	2015	Morphological	157	1.5T	PAB	25	9	81	No
Couñago et al[6]	2015	Multiparametric	274	3T	PAB	90.4	32.8	43.8 or 52.53	Yes
Pullini et al[28]	2016	Multiparametric	44	3T	PAB	65.9	40.9	NR	No
Liauw et al[27]	2016	Multiparametric	122	3T	PAB	NR	18	22	No

¹Exclusive assessment of the CTV change;

²Data from T1-T2 to T3-T4 upstaging;

³Values according to the HT criteria in intermediate-risk patients. PAB: Phased-array-bodycoil; NR: Not reported; CTV: Clinical target volume; HT: Hormonal therapy.